Update: UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble

02:46 PM EDT, 09/29/2026 (MT Newswires) -- (Updates with additional details in the second and fourth paragraphs, and the latest stock move in the last paragraph.) UniQure (QURE) reported on Tuesday additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease that showed less pronounced benefits at 48 months. The company said the primary endpoint of composite Unified Huntington's Disease Rating Scale did not reach statistical significance at 48 months, with a 44% slowing of disease progression among 12 high-dose patients, compared with the updated 36-month data of 80% slowing of disease progression among 15 high-dose patients. Total functional capacity delivered a 61% slowing of disease progression at 48 months, compared with the updated 36-month data of 67%, the company said. The company said its biologics license application for the accelerated approval of AMT-130 in Huntington's disease did not include the 48-month data. The company's shares fell more than 37% in Tuesday trading. Price: 24.63, Change: -14.48, Percent Change: -37.02